Defining the causes of heterogeneous riboucleotide reductase gene transcription in response to DNA damage and anti-cancer drugs

定义响应 DNA 损伤和抗癌药物的异质核糖核苷酸还原酶基因转录的原因

• 批准号: 280186
• 负责人: Kaern Mads
• 金额: $ 26.54万
• 依托单位: University of Ottawa
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2013
• 资助国家: 加拿大
• 起止时间: 2013-03-01 至 2016-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=280186&lang=en
• 关键词: Dna Damage Checkpoint; Drug Responses; Quantitative Biology; Systems Biology Of Model Organisms; Transcriptional Regulation

The outcome of drug therapy can vary significantly from one individual to the next. Studies of model systems, such as breast and lung cancer cell lines, have shown that variability in drug responses can originate at the level of individual cells, even und

药物治疗的结果因人而异。对模型系统（例如乳腺癌和肺癌细胞系）的研究表明，药物反应的变异性可能起源于单个细胞水平，甚至是单个细胞水平。